Skip to content
synovial sarcoma foundation
  • About
    • Mission
    • Initiatives
    • Affiliations
    • Leadership
    • Board of Directors
    • Medical Advisory Board
    • Careers
  • Resources
    • Synovial Sarcoma FAQ
    • Treatments
    • Clinical Trials & Therapies
    • Synovial Sarcoma Patient Survey
    • Synovial Sarcoma Tumor Board
    • Patient Stories
    • Patient Resources
    • Eddie’s Story
    • Video Resources
    • SSF Ambassador Program
  • Research Programs
    • Clinical Research
    • Tumor Glow
    • Synovial Sarcoma Registry
  • Latest News
Donate

Send us a note

Please fill out the form below and we will gladly respond as soon as possible.



    Research

    Arizona Pioneers New Immune Therapy for Synovial Sarcoma Treatment

    December 12, 2025 joshs Comments Off on Arizona Pioneers New Immune Therapy for Synovial Sarcoma Treatment
    Three scientists in lab coats and safety glasses work together in a laboratory. One woman holds a clipboard and takes notes while the two men, one beside a microscope, listen and discuss results.

    In a groundbreaking advancement in cancer treatment, a patient with synovial sarcoma in Arizona has become the first in the state to receive a cutting-edge immune-cell therapy, TECELRA, at the HonorHealth Research Institute in Scottsdale.

    Synovial sarcoma is a rare soft-tissue cancer that primarily affects large joints in the arms and legs, though it can manifest anywhere in the body. The innovative TECELRA therapy specifically targets a protein linked to the MAGEA4 gene, which is frequently expressed in tumors associated with this type of cancer.

    [Original article via Mirage News]

    Dr. Justin Moser, an associate clinical investigator at the HonorHealth Research Institute and a specialist in melanoma, shared promising updates, stating, “The patient tolerated the cell infusion well, with early signs of tumor shrinkage.” This therapy has shown potential benefits for over 40 percent of patients with refractory synovial sarcoma—those whose cancer has progressed despite various treatments. Remarkably, many have experienced lasting benefits even after a year.

    This promising development highlights the importance of ongoing research and innovation in the fight against synovial sarcoma and offers hope to those affected by this challenging diagnosis.

    For more detailed information, please refer to the original article.

    For more detailed information about Synovial Sarcoma resources and support, please visit our website.

    • ground breaking
    • immune-cell therapy
    • Synovial Sarcoma Foundation
    • synovial sarcoma treatment
    • TECELRA
    joshs

    Post navigation

    Previous
    Next

    Search

    Categories

    • Black Flag Racing (2)
    • Case Study (5)
    • Children (1)
    • CHOP (3)
    • Clinical Trial (4)
    • Development (12)
    • Dr. Theodore Laetsch (3)
    • Education (27)
    • Europe Expansion (1)
    • Healthcare (13)
    • Latest News (22)
    • Patient Story (1)
    • Programs (1)
    • Rare Cancer (7)
    • Rare Cancer Funding (2)
    • Research (21)
    • SSF Ambassador Program (1)
    • Synovial Sarcoma Conference (2)
    • Synovial Sarcoma Registry (7)
    • Teresa Belluco (1)
    • Tumor Board (2)

    Recent posts

    • A doctor in a white coat with a stethoscope around their neck holds a tablet device, standing in a medical setting with a patient lying on a bed in the background.
      Synovial Sarcoma of the Tibial Nerve: A Case of Diagnostic Ambiguity and Limb Salvage
    • A scientist wearing blue gloves adjusts a microscope slide.
      Can We Reactivate T Cells After TCR-T Therapy Stops Working?
    • Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
      Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    Tags

    #AYACancer #CancerResearch #CaseReport #CellTherapy #ClinicalTrials #Immunotherapy #KnowYourOptions #MAGEA4 #MolecularDiagnostics #NYESO1 #PatientAdvocacy #RareCancer #RareDisease #Sarcoma #SarcomaAwareness #SoftTissueSarcoma #SS18SSX #SynovialSarcoma #SynovialSarcomaFoundation #TumorBoard Afami-cel Afamitresgene autoleucel Cancer Research CHOP immunotherapy MAGE-A4 synovial sarcoma NY-ESO-1 synovial sarcoma precision medicine Rare Cancer rare cancer research rare soft tissue sarcoma research sarcoma research sarcoma treatment soft tissue sarcoma Synovial Sarcoma synovial sarcoma biomarker testing synovial sarcoma diagnosis Synovial Sarcoma Foundation synovial sarcoma immunotherapy synovial sarcoma treatment T-Cell Therapy targeted therapy TCR Therapy TECELRA

    Related posts

    A scientist wearing blue gloves adjusts a microscope slide.
    Clinical Trial, Development

    Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    November 3, 2026 ayushis Comments Off on Can We Reactivate T Cells After TCR-T Therapy Stops Working?

    A new pilot trial at Northwestern University is asking one of the most important questions in synovial sarcoma treatment: when TCR-T therapy stops working, are the T cells truly gone, or can they be brought back to life? Background: The Promise and the Limit of TCR-T Therapy TCR-T cell therapy represents a major advance for […]

    Hands wearing blue nitrile gloves draw liquid from a small glass vial into a syringe, with a rack of test tubes in the background.
    Latest News, Synovial Sarcoma Registry

    Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    October 28, 2026 ayushis Comments Off on Why Every Tumor Sample Matters: What a New Sarcoma Biobank Study Means for Synovial Sarcoma

    A new study in Advanced Science (October 12, 2026) shows what becomes possible when patients donate tumor tissue and researchers pair it with detailed clinical and genetic data. The same idea drives the Synovial Sarcoma Registry and Biorepository, and every patient who joins makes the next study possible. What the study found Over ten years, […]

    Close-up of blue gloved hands adjusting a microscope with two visible objective lenses, focusing on a glass slide in a laboratory setting.
    Education, Research

    The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    September 14, 2026 ayushis Comments Off on The Cells Around the Tumor May Hold the Key to Improving Immunotherapy in Synovial Sarcoma

    A new study published in PLOS One by Ji-Yong Sung, Jin-Hong Kim, and Yi-Jun Kim from Seoul National University and Ewha Womans University, South Korea, examines a type of cell found in the tissue surrounding tumors, called cancer-associated fibroblasts (CAFs), and asks whether they can predict how a sarcoma patient will respond to immunotherapy. What […]

    The Synovial Sarcoma Foundation is a registered 501(c)(3) nonprofit organization. Tax ID number is 33-4027591. Contributions to the Synovial Sarcoma Foundation are tax-deductible to the extent permitted by law.

    • Terms & conditions
    • Privacy policy
    synovial sarcoma foundation
    • community@synovialsarcoma.org
    1025 Thomas Jefferson St. NW, Suite W-3200, Washington DC 20007
    Facebook-f X-twitter Linkedin

    Navigation

    • About
    • Research Programs
    • Patient Stories
    • Resources

    Stay in touch